vs

Side-by-side financial comparison of LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) and PEDEVCO CORP (PED). Click either name above to swap in a different company.

LIFECORE BIOMEDICAL, INC. \DE\ is the larger business by last-quarter revenue ($31.1M vs $23.1M, roughly 1.3× PEDEVCO CORP). LIFECORE BIOMEDICAL, INC. \DE\ runs the higher net margin — -32.1% vs -36.8%, a 4.7% gap on every dollar of revenue. On growth, PEDEVCO CORP posted the faster year-over-year revenue change (118.2% vs -4.5%). Over the past eight quarters, PEDEVCO CORP's revenue compounded faster (68.6% CAGR vs -0.1%).

LIFECORE BIOMEDICAL, INC. is a biomedical firm focused on developing and manufacturing high-quality hyaluronic acid-based biomaterials. It operates three core segments: medical application products, pharmaceutical solutions, and personal care ingredients, with main markets spanning North America, Europe and the Asia-Pacific, supplying to leading medical device, pharmaceutical and cosmetic brand partners.

PEDEVCO Corp is an independent energy company specializing in the acquisition, exploration, development, and production of oil and natural gas assets. It primarily holds and operates onshore resource properties across continental US basins, serving domestic wholesale, utility, and industrial energy customer segments.

LFCR vs PED — Head-to-Head

Bigger by revenue
LFCR
LFCR
1.3× larger
LFCR
$31.1M
$23.1M
PED
Growing faster (revenue YoY)
PED
PED
+122.7% gap
PED
118.2%
-4.5%
LFCR
Higher net margin
LFCR
LFCR
4.7% more per $
LFCR
-32.1%
-36.8%
PED
Faster 2-yr revenue CAGR
PED
PED
Annualised
PED
68.6%
-0.1%
LFCR

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
LFCR
LFCR
PED
PED
Revenue
$31.1M
$23.1M
Net Profit
$-10.0M
$-8.5M
Gross Margin
25.0%
Operating Margin
-9.9%
-21.3%
Net Margin
-32.1%
-36.8%
Revenue YoY
-4.5%
118.2%
Net Profit YoY
-52.0%
-243.5%
EPS (diluted)
$-0.29
$-2.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LFCR
LFCR
PED
PED
Q4 25
$23.1M
Q3 25
$31.1M
$7.0M
Q2 25
$7.0M
Q1 25
$35.2M
$8.7M
Q4 24
$32.6M
$10.6M
Q3 24
$24.7M
$9.1M
Q2 24
$11.8M
Q1 24
$35.7M
$8.1M
Net Profit
LFCR
LFCR
PED
PED
Q4 25
$-8.5M
Q3 25
$-10.0M
$-325.0K
Q2 25
$-1.7M
Q1 25
$-14.8M
$140.0K
Q4 24
$-6.6M
$5.9M
Q3 24
$-16.2M
$2.9M
Q2 24
$2.7M
Q1 24
$15.6M
$773.0K
Gross Margin
LFCR
LFCR
PED
PED
Q4 25
Q3 25
25.0%
Q2 25
Q1 25
28.0%
Q4 24
34.0%
Q3 24
21.8%
Q2 24
Q1 24
33.3%
Operating Margin
LFCR
LFCR
PED
PED
Q4 25
-21.3%
Q3 25
-9.9%
-12.0%
Q2 25
-32.2%
Q1 25
-25.7%
1.7%
Q4 24
-6.0%
-12.9%
Q3 24
-46.9%
31.3%
Q2 24
22.3%
Q1 24
-2.5%
7.6%
Net Margin
LFCR
LFCR
PED
PED
Q4 25
-36.8%
Q3 25
-32.1%
-4.7%
Q2 25
-24.0%
Q1 25
-42.0%
1.6%
Q4 24
-20.2%
56.0%
Q3 24
-65.7%
32.2%
Q2 24
22.7%
Q1 24
43.8%
9.5%
EPS (diluted)
LFCR
LFCR
PED
PED
Q4 25
$-2.23
Q3 25
$-0.29
$0.00
Q2 25
$-0.02
Q1 25
$-0.47
$0.00
Q4 24
$-0.25
$2.69
Q3 24
$-0.53
$0.03
Q2 24
$0.03
Q1 24
$0.42
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LFCR
LFCR
PED
PED
Cash + ST InvestmentsLiquidity on hand
$18.9M
$3.2M
Total DebtLower is stronger
$136.0M
Stockholders' EquityBook value
$-10.5M
$207.4M
Total Assets
$235.2M
$375.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LFCR
LFCR
PED
PED
Q4 25
$3.2M
Q3 25
$18.9M
$10.9M
Q2 25
$8.5M
Q1 25
$5.4M
$10.4M
Q4 24
$9.5M
$4.0M
Q3 24
$4.6M
Q2 24
$6.1M
Q1 24
$13.3M
Total Debt
LFCR
LFCR
PED
PED
Q4 25
Q3 25
$136.0M
Q2 25
Q1 25
$124.9M
Q4 24
$111.3M
Q3 24
$106.3M
Q2 24
Q1 24
$97.1M
Stockholders' Equity
LFCR
LFCR
PED
PED
Q4 25
$207.4M
Q3 25
$-10.5M
$115.4M
Q2 25
$115.2M
Q1 25
$2.2M
$116.2M
Q4 24
$15.4M
$115.6M
Q3 24
$-3.9M
$106.5M
Q2 24
$103.2M
Q1 24
$17.7M
$100.0M
Total Assets
LFCR
LFCR
PED
PED
Q4 25
$375.9M
Q3 25
$235.2M
$135.9M
Q2 25
$136.8M
Q1 25
$237.7M
$145.6M
Q4 24
$255.4M
$128.3M
Q3 24
$246.8M
$114.3M
Q2 24
$111.0M
Q1 24
$246.2M
$118.3M
Debt / Equity
LFCR
LFCR
PED
PED
Q4 25
Q3 25
Q2 25
Q1 25
56.05×
Q4 24
7.20×
Q3 24
Q2 24
Q1 24
5.49×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LFCR
LFCR
PED
PED
Operating Cash FlowLast quarter
$1.8M
$-2.1M
Free Cash FlowOCF − Capex
$25.0K
FCF MarginFCF / Revenue
0.1%
Capex IntensityCapex / Revenue
5.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-16.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LFCR
LFCR
PED
PED
Q4 25
$-2.1M
Q3 25
$1.8M
$7.4M
Q2 25
$-420.0K
Q1 25
$1.2M
$5.9M
Q4 24
$-6.1M
$4.2M
Q3 24
$-613.0K
$8.3M
Q2 24
$4.6M
Q1 24
$-1.4M
$-4.3M
Free Cash Flow
LFCR
LFCR
PED
PED
Q4 25
Q3 25
$25.0K
Q2 25
Q1 25
$-4.3M
Q4 24
$-8.6M
Q3 24
$-4.0M
Q2 24
Q1 24
$-7.8M
FCF Margin
LFCR
LFCR
PED
PED
Q4 25
Q3 25
0.1%
Q2 25
Q1 25
-12.1%
Q4 24
-26.3%
Q3 24
-16.3%
Q2 24
Q1 24
-21.8%
Capex Intensity
LFCR
LFCR
PED
PED
Q4 25
Q3 25
5.6%
Q2 25
Q1 25
15.5%
Q4 24
7.5%
Q3 24
13.9%
Q2 24
Q1 24
17.8%
Cash Conversion
LFCR
LFCR
PED
PED
Q4 25
Q3 25
Q2 25
Q1 25
42.34×
Q4 24
0.71×
Q3 24
2.83×
Q2 24
1.71×
Q1 24
-0.09×
-5.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LFCR
LFCR

Transferred At Point In Time$26.6M85%
Transferred Over Time$4.5M15%

PED
PED

Segment breakdown not available.

Related Comparisons